WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and the Medical College of Wisconsin, today announced the manuscript “Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for PDAC'' has published online and in print in Gastroenterology, the premier journal in the field of gastrointestinal disease.

马萨诸塞州沃尔瑟姆（商业新闻短讯）--人工智能驱动的分子和免疫分析解决方案的领先供应商BostonGene和威斯康星州医学院今天宣布了手稿“基于转录组学的微环境分类揭示了PDAC的精准医学策略”，该手稿已在胃肠疾病领域的首要期刊《胃肠病学》上在线和印刷。

BostonGene’s artwork was also chosen for the cover of the May publication. The journal highlights original research, reviews and expert insights in adult and pediatric gastroenterology and hepatology, covering clinical, translational and basic aspects of the digestive system, liver, pancreas and nutrition.

BostonGene的作品也被选为五月出版物的封面。该杂志重点介绍了成人和儿科胃肠病学和肝病学的原始研究，评论和专家见解，涵盖了消化系统，肝脏，胰腺和营养的临床，转化和基本方面。

The study identified four distinct tumor microenvironment (TME) subtypes, unveiling a promising path forward in the fight against PDAC and underscoring the importance of considering TME features in personalized therapeutic strategies..

该研究确定了四种不同的肿瘤微环境（TME）亚型，揭示了对抗PDAC的有希望的途径，并强调了在个性化治疗策略中考虑TME特征的重要性。。

Pancreatic ductal adenocarcinoma (PDAC) has long been notorious for its aggressive nature and genetic complexity, making it difficult for doctors to predict how patients will respond to treatment and for scientists to develop effective predictive biomarkers and targeted therapies. To address these unmet needs, Ben George, MD, at the Medical College of Wisconsin (MCW) in collaboration with BostonGene, led a study utilizing a transcriptomic profiling platform to classify the TME of PDAC based on functional gene expression signatures.

胰腺导管腺癌（PDAC）长期以来因其侵略性和遗传复杂性而臭名昭著，这使得医生很难预测患者对治疗的反应，科学家也很难开发有效的预测性生物标志物和靶向治疗。为了解决这些未满足的需求，威斯康星医学院（MCW）的Ben George医学博士与BostonGene合作，领导了一项利用转录组分析平台的研究，根据功能基因表达特征对PDAC的TME进行分类。

This innovative approach analyzed data from publicly available PDAC datasets and was further validated in a clinically annotated, independent cohort of PDAC patients from the LaBahn Pancreatic Cancer Program, part of the MCW Cancer Center..

这种创新的方法分析了来自公开可用的PDAC数据集的数据，并在来自LaBahn胰腺癌计划（MCW癌症中心的一部分）的临床注释的独立PDAC患者队列中得到了进一步验证。。

“For a long while, the scientific community believed that pancreatic cancer was not responsive to immunotherapy, which uses a person’s own immune system to fight cancer. We’ve since made new discoveries that show that pancreatic cancer that spreads to the lungs is biologically distinct, prognostically favorable, and potentially responsive to immunotherapy compared to those that spread to the liver,” said Ben George, MD, William F.

“很长一段时间以来，科学界认为胰腺癌对免疫疗法没有反应，免疫疗法利用人体自身的免疫系统来对抗癌症。我们后来有了新的发现，表明与扩散到肝脏的胰腺癌相比，扩散到肺部的胰腺癌在生物学上是独特的，预后良好，并且可能对免疫疗法有反应，”医学博士本·乔治（BenGeorge）说。

Stapp Endowed Chair; Professor of Medicine and Medical Director, Cancer Clinical Trials Program at the Medical College of Wisconsin. “Together with BostonGene, we hope to further characterize the biologically distinct PDAC subtypes and investigate how different treatments can modify the TME of pancreatic cancers.

Stapp捐赠主席；威斯康星医学院医学教授兼癌症临床试验项目医学主任。“与BostonGene一起，我们希望进一步表征生物学上不同的PDAC亚型，并研究不同的治疗方法如何改变胰腺癌的TME。

Our goal is to design prospective clinical trials, which will be made available through the MCW Cancer Center, to test various immunomodulatory strategies based on these four subtypes.”.

我们的目标是设计前瞻性临床试验，该试验将通过MCW癌症中心提供，以测试基于这四种亚型的各种免疫调节策略。”。

As part of the collaboration, BostonGene utilized an artificial intelligence (AI)-driven algorithm to reconstruct the transcriptomic data and identified four distinct TME subtypes: immune-enriched (IE), immune-enriched with fibrosis (IE/F), fibrotic (F) and immune-depleted (D). Importantly, patients with immune-enriched subtypes, IE and IE/F, demonstrated a more favorable prognosis and showed potential responsiveness to immunotherapy than those classified as F and D..

作为合作的一部分，BostonGene利用人工智能（AI）驱动的算法重建转录组数据，并确定了四种不同的TME亚型：免疫富集（IE），免疫富集纤维化（IE/F），纤维化（F）和免疫耗竭（D）。重要的是，具有免疫富集亚型IE和IE/F的患者表现出比F和D类患者更有利的预后，并显示出对免疫治疗的潜在反应性。。

'We're excited to unveil our latest research, which sheds light on the intricate tumor microenvironment of PDAC,' said Ben George. 'These results pave the way for transcriptomic-based immunotherapeutic strategies in PDAC, bringing us closer to personalized treatment approaches for this challenging disease.'.

本·乔治（BenGeorge）说：“我们很高兴能公布我们的最新研究，该研究揭示了PDAC复杂的肿瘤微环境。这些结果为PDAC中基于转录组学的免疫治疗策略铺平了道路，使我们更接近于针对这种具挑战性疾病的个性化治疗方法。”。

'Our findings not only define a subgroup of PDAC patients who may benefit from immunotherapeutic interventions but also sets the stage for prospective clinical trials to validate the predictive utility of these transcriptomic TME PDAC subtypes,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene..

“我们的研究结果不仅确定了可能受益于免疫治疗干预的PDAC患者亚组，而且为前瞻性临床试验奠定了基础，以验证这些转录组TME PDAC亚型的预测效用，”BostonGene首席医学官Nathan Fowler医学博士说。。

About BostonGene Corporation

关于BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results.

BostonGene的使命是提供变革性的人工智能集成分子分析和生物标志物发现，以精确匹配治疗方法，改善癌症和其他免疫相关疾病患者的生活。BostonGene的礼宾服务模型使用多组学方法提供定制的客户解决方案，该方法优先考虑现实世界的影响，以优化护理标准疗法，加速研究并提供具有成本效益的，可测量的数据驱动的结果。

BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient.

BostonGene的测试揭示了每位患者独特疾病特征的关键驱动因素，包括免疫微环境的深入概况，可行的突变，对多种疗法的反应的生物标志物以及推荐的疗法。通过这些综合分析，BostonGene的测试为每位患者的治疗决策制定了个性化的路线图。

For more information, visit BostonGene at http://www.BostonGene.com..

有关更多信息，请访问BostonGenehttp://www.BostonGene.com..

About the Medical College of Wisconsin

关于威斯康星医学院

With a history dating back to 1893, The Medical College of Wisconsin is dedicated to leadership and excellence in education, patient care, research and community engagement. More than 1,400 students are enrolled in MCW’s medical school and graduate school programs in Milwaukee, Green Bay and Central Wisconsin.

威斯康星医学院的历史可以追溯到1893年，它致力于在教育、病人护理、研究和社区参与方面发挥领导作用和卓越表现。1400多名学生就读于密尔沃基、格林湾和威斯康星州中部的MCW医学院和研究生院项目。

MCW’s School of Pharmacy opened in 2017. A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin. In the last 10 years, faculty received more than $1.5 billion in external support for research, teaching, training and related purposes.

MCW的药学院于2017年开业。作为一个主要的国家研究中心，MCW是密尔沃基大都会地区最大的研究机构，也是威斯康星州第二大的研究机构。在过去的10年中，教师们获得了超过15亿美元的外部支持，用于研究、教学、培训和相关目的。

This total includes highly competitive research and training awards from the National Institutes of Health (NIH). Annually, MCW faculty direct or collaborate on more than 3,100 research studies, including clinical trials. Additionally, more than 1,600 physicians provide care in virtually every specialty of medicine for more than 2.8 million patients annually..

这一总数包括来自美国国立卫生研究院（NIH）的极具竞争力的研究和培训奖。每年，MCW教员指导或合作进行3100多项研究，包括临床试验。此外，每年有1600多名医生为280多万患者提供几乎所有医学专业的护理。。